Apteka Jutrzenka Spółka z Ograniczoną Odpowiedzialnością (KRS 0000668396, NIP 7123056303) is a Polish company, headquartered in Lublin, Lubelskie voivodeship. APTEKA JUTRZENKA operates in: Dispensing chemist in specialised stores (PKD 47.73.Z). Industry: Retail trade. The company has been listed in the National Court Register since March 14, 2017. APTEKA JUTRZENKA's most recently reported net revenue was 2.4 M PLN for 2024.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Apteka Jutrzenka
Identity
- Name
- Apteka Jutrzenka Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- March 14, 2017
- Registry status as of
- December 4, 2025
- Latest entry
- October 9, 2025
- Founding act
- 25.01.2017 R., NOTARIUSZ MAŁGORZATA BEDNARA - KOWAL, KANCELARIA NOTARIALNA W LUBLINIE, REPERTORIUM A NR 548/2017.
Articles of association history (2)
- January 25, 2017: 25.01.2017 R., NOTARIUSZ MAŁGORZATA BEDNARA - KOWAL, KANCELARIA NOTARIALNA W LUBLINIE, REPERTORIUM A NR 548/2017.
- January 21, 2025: 21.01.2025, REPERTORIUM A NR 477/2025,NOTARIUSZ PAWEŁ ROŻEN, KANCELARIA NOTARIALNA W LUBLINIE, UCHYLENIE DOTYCHCZASOWEGO BRZMIENIA UMOWY SPÓLKI, PRZYJĘCIE TEKSTU JEDNOLITEGO UMOWY SPÓŁKI,
Activities
Main activity
47.73.ZDispensing chemist in specialised stores
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. JUTRZENKI, 4, 20-538, LUBLIN, POLSKA
- Voivodeship
- LUBELSKIE
- District
- LUBLIN
- APTEKA.JUTRZENKA@O2.PL
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-94022-37157-WEUCE-14
- Coordinates
- 51.2464, 22.5683approx.
Risk and payment profile - Apteka Jutrzenka
Credibility rating
45.1 / 100
Average credibility
Insolvency risk
Low
Elevated threat
Closure risk
20
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/9 yrs
Board changes
1
1/9 yrs
PKD changes
1
1/9 yrs
Name changes
0
0/9 yrs
Data from 9 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: D (45/100)
Trend: deteriorating (-16.1 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2018–2024
Current: 81.6 K PLN
Safe: 24.5 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Apteka Jutrzenka
Founded
March 14, 2017
9 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
LUBLIN
LUBELSKIE
Primary PKD
47.73.Z
Dispensing chemist in specialised stores
Share capital
10.0 K PLN
200 shares total
Shareholders
2
shareholders
Board
3 people
Filed years
7 years
2018–2024 · profitable: 3/7
Registry entries
21
latest: October 9, 2025
Risk signals
Revenue
2.4 M PLN
2024
Net profit
-29.4 K PLN
2024
Assets
309.7 K PLN
2024
Equity
261.7 K PLN
2024
EBITDA
-22.1 K PLN
2024
Valuation
344.2 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Apteka Jutrzenka.
No ratings
Related articles
News
Ambra in 2026: PLN 48.1 m capex (+212%), PLN 1.10 dividend three years running, Cydr Lubelski plus Romanian Zarea as the premium engine
Warsaw-based Ambra S.A. (KRS 0000041726, ul. Puławska 336) closed H1 of fiscal 2025/2026 with PLN 556.8 m of revenue and PLN 49.0 m of net profit, while raising capex by 212% to PLN 48.1 m - mainly for the soft-drinks line in Wola Duża and the PLN 11.9 m acquisition of a Romanian company. Despite the aggressive investment cycle the board keeps a PLN 1.10 dividend per share for the third year running (~5.9% yield).
News
Answear in 2026: first full year without MCI, PLN 9.3 m net profit, but the supervisory board cuts the 2026 EBITDA target from PLN 100 m to PLN 90 m
Kraków-based Answear.com S.A. (KRS 0000816066) closed 2025 with revenue of PLN 1.7 bn (+13% YoY), EBITDA of PLN 56 m (+63%) and net profit of PLN 9.3 m - a return to the black after a PLN 10 m loss in 2024. Poland grew +31%, but CEE was under FX pressure (hryvnia -11% vs PLN), and a weak Q4 (EBITDA -71% YoY) forced the supervisory board to cut the 2026 EBITDA target from PLN 100 m to PLN 90 m and the target price from PLN 50 to PLN 45. It is the first full year after MCI's exit from the shareholder base (10 June 2025); the Bajołek brothers retain control (57.8%).
